# B-Cells and Plasmablasts as Architects of Autoimmune Disease: From Molecular Footprints to Precision Therapeutics

## TL;DR

This paper explores how different types of B-cells and plasmablasts contribute to autoimmune diseases and how understanding these can lead to better, personalized treatments.

## Contribution

The paper introduces a novel endotype-based framework for B-cell populations in autoimmune diseases, linking specific B-cell profiles to therapeutic responses and precision medicine strategies.

## Key findings

- B-cell populations in autoimmune diseases can be classified into four distinct endotypes with unique biomarker signatures and therapeutic vulnerabilities.
- IgG subclass distribution determines treatment response patterns, with IgG4-dominant diseases responding rapidly to B-cell depletion and IgG1/IgG3-dominant diseases resisting anti-CD20 therapy.
- Endotype-based patient stratification can guide mechanism-aligned therapeutic selection, potentially improving treatment outcomes.

## Abstract

What are the main findings?
B-cell populations in systemic autoimmune diseases can be classified into distinct immunological endotypes—extrafollicular/IFN-high, germinal center/plasma cell-anchored, BAFF-dependent, and tissue-conditioned/fibro-inflammatory—each characterized by specific biomarker signatures, autoantibody profiles, and biological vulnerabilities.IgG subclass distribution (IgG1/IgG3 versus IgG4 predominance) critically determines therapeutic response patterns, with IgG4-mediated diseases showing rapid responses to B-cell depletion due to short-lived plasmablast dependence, while IgG1/IgG3-dominant diseases often resist anti-CD20 therapy due to long-lived plasma cell persistence.

B-cell populations in systemic autoimmune diseases can be classified into distinct immunological endotypes—extrafollicular/IFN-high, germinal center/plasma cell-anchored, BAFF-dependent, and tissue-conditioned/fibro-inflammatory—each characterized by specific biomarker signatures, autoantibody profiles, and biological vulnerabilities.

IgG subclass distribution (IgG1/IgG3 versus IgG4 predominance) critically determines therapeutic response patterns, with IgG4-mediated diseases showing rapid responses to B-cell depletion due to short-lived plasmablast dependence, while IgG1/IgG3-dominant diseases often resist anti-CD20 therapy due to long-lived plasma cell persistence.

What are the implications of the main findings?
Endotype-based patient stratification enables mechanism-aligned therapeutic selection—directing JAK inhibitors and anti-CD19 therapies toward extrafollicular-dominant patients, proteasome inhibitors or CAR-T towards plasma cell-anchored disease, and BAFF inhibitors toward BAFF-dependent phenotypes—potentially improving response rates and reducing treatment failures.The convergence of B-cell endotyping frameworks across organ-specific and systemic autoimmune diseases suggests that shared immunological architectures, rather than traditional diagnostic boundaries, may better guide precision medicine approaches in clinical practice.

Endotype-based patient stratification enables mechanism-aligned therapeutic selection—directing JAK inhibitors and anti-CD19 therapies toward extrafollicular-dominant patients, proteasome inhibitors or CAR-T towards plasma cell-anchored disease, and BAFF inhibitors toward BAFF-dependent phenotypes—potentially improving response rates and reducing treatment failures.

The convergence of B-cell endotyping frameworks across organ-specific and systemic autoimmune diseases suggests that shared immunological architectures, rather than traditional diagnostic boundaries, may better guide precision medicine approaches in clinical practice.

B-cells and plasmablasts have emerged as central organizers of autoimmune pathogenesis, extending far beyond their classical role as antibody-producing cells to orchestrate immune circuits, tissue microenvironments, and therapeutic trajectories. Advances in single-cell technologies, high-dimensional cytometry, and B-cell receptor sequencing have uncovered a dynamic continuum of B-cell differentiation programs that drive clinical heterogeneity across systemic autoimmune diseases. Plasmablasts, in particular, have gained recognition as highly responsive sensors of immune activation: they expand during flares, encode interferon-driven and extrafollicular responses, and correlate with disease severity. Autoantibody profiles, long viewed as static diagnostic signatures, are now understood as durable molecular footprints of distinct B-cell pathways. In this review, we propose an endotype-based framework integrating B-cell circuits with clinical phenotypes, illustrate therapeutic decision-making through mechanistic case vignettes, and outline future strategies combining immunomonitoring, multi-omics, and precision therapeutics. We further address translational challenges and discuss complementary approaches, including T-cell modulation, FcRn inhibition, and antigen-specific tolerization.